Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients
- PMID: 34049488
- PMCID: PMC8164226
- DOI: 10.1186/s12872-021-02083-6
Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients
Abstract
Background: Soluble suppression of tumorigenesis-2 (sST2), Procollagen Type III N-Terminal Peptid (PIIINP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been verified their role in predicting survival in acutely decompensated heart failure (ADHF). However, whether their combination could improve more specific and sensitive prognostic information than NT-proBNP alone remains unclear.
Methods: This was a prospective study, in which 217 ADHF patients at admission were enrolled from November 2018 and August 2019 (mean age 66.18 years ± 13.60, 63.98% male). The blood samples were collected to measure the concentrations of NT-proBNP, sST2 and PIIINP in the first 24 h of hospitalizations. All-cause mortality was registered for all patients after they were discharge over a median period of 339 days.
Results: In univariate Cox analysis, the three biomarkers were predictive of short-term mortality of ADHF patients. After adjusted for some clinical variables including age, admission systolic blood pressure, peripheral edema on admission, history of chronic obstructive pulmonary disease, admission sodium < 135 mmol/L, admission hemoglobin, NT-proBNP, sST2 and PIIINP was significantly associated with the poor outcome (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.14-1.53, P < 0.01; HR 1.21, 95% CI 1.03-1.43, P = 0.020; HR 1.40, 95% CI 1.08-1.81, P = 0.011). After added with Log2 PIIINP, but not Log2 sST2, the area under the curves (AUC) in the model of clinical variables and Log2 NT-proBNP could increase from 0.79 to 0.85 (95% CI 0.0071-0.10, P = 0.024). Furthermore, compared with the model of clinical variables, Log2 NT-proBNP, the improvement in the prognostic model of clinical variables, Log2 NT-proBNP and Log2 PIIINP had statistical significance [net reclassification improvement (NRI) 0.31, P = 0.018; integrated discrimination improvement (IDI) 0.068, P < 0.01].
Conclusions: NT-proBNP, sST2 and PIIINP are independent prognostic factors for all-cause mortality in ADHF patients. Furthermore, the combination of NT-proBNP and PIIINP may provide incremental prognostic value over NT-proBNP in the survival of ADHF patients.
Keywords: Biomarkers; Heart failure; Myocardial fibrosis; Prognosis.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.Int J Cardiol. 2013 Oct 3;168(3):2120-6. doi: 10.1016/j.ijcard.2013.01.005. Epub 2013 Feb 6. Int J Cardiol. 2013. PMID: 23395457
-
A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.Heart. 2014 Jan;100(2):115-25. doi: 10.1136/heartjnl-2013-303632. Epub 2013 Oct 31. Heart. 2014. PMID: 24179162
-
Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure.ESC Heart Fail. 2024 Oct;11(5):2857-2868. doi: 10.1002/ehf2.14860. Epub 2024 May 21. ESC Heart Fail. 2024. PMID: 38773746 Free PMC article.
-
The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP.Minerva Cardioangiol. 2016 Apr;64(2):157-64. Epub 2015 Sep 15. Minerva Cardioangiol. 2016. PMID: 26373781 Review.
-
N-terminal prohormone B-type natriuretic peptide and cardiovascular risk in stable coronary artery disease: a meta-analysis of nine prospective studies.Rev Cardiovasc Med. 2013;14(2-4):e92-8. doi: 10.3909/ricm0644. Rev Cardiovasc Med. 2013. PMID: 24448259 Review.
Cited by
-
Soluble ST2 for predicting heart failure, atrial fibrillation and death in patients with coronary heart disease with or without renal insufficiency.Heliyon. 2024 Apr 20;10(9):e29804. doi: 10.1016/j.heliyon.2024.e29804. eCollection 2024 May 15. Heliyon. 2024. PMID: 38698979 Free PMC article.
-
Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure.Front Cardiovasc Med. 2022 Feb 10;9:821553. doi: 10.3389/fcvm.2022.821553. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35224052 Free PMC article.
References
-
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509. - DOI - PubMed
-
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials